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Abstract
We have compared the activity of several K«- or Ld-restricted antigenic peptides as competitors in
a functional competition assay using cytolytic T lymphocyte (CTL) clones. All of four unrelated
Kd-restricted peptides tested could compete with each other but not with the Ld-restricted
peptide P 9 1 A M 2 - 2 4 (P91A). Moreover, the P91A peptide failed to compete with the four
Kd-restricted peptides. In contrast, another Unrestricted peptide [mouse cytomegalovirus (MCMV)
pp89 167-176] could clearly compete with both Kd- and Ld-restricted peptides. The comparison
of a series of modified MCMV pp89 peptides suggested that distinct structural features allow the
interaction of the peptide with the two different MHC class I molecules. We showed previously
that the competitor activity of two different Kd-restricted antigenic peptides was reduced
substantially upon Ala substitution of the single Tyr residues present in these peptides. We now
show a similar effect for two additional K«-restricted peptides. Our results thus suggest that Tyr
may function as an 'anchor' residue for many antigenic peptides that bind to the Kd molecule.
Molecular modeling of the presumed antigen-binding site of the Kd molecule revealed the
presence of two deep cavities that may be involved in binding peptide amino acid side chains.
A model illustrating one possible interaction of a Tyr-containing peptide with the K<< molecule
is presented.
Introduction
T lymphocytes recognize antigen in the context of specific
cell-surface molecules encoded by the major histocompatibility
complex (MHC) (1,2). In many cases, T cell antigens can be
mimicked by defined natural or synthetic peptides (3,4). Analysis
of the structure of the MHC class I molecule HLA-A2 by X-ray
crystallography showed that most of the polymorphic residues
are located within a groove formed by two a-helices overlying
an eight-strand /3-sheet (5,6). This region was therefore proposed
as the binding site for antigenic peptides. Based on sequence
similarities, an analogous structure and antigen-binding site was
proposed for MHC class II molecules (7).
Analysis of the structural requirements for the specific
interaction of antigenic peptides with MHC class II molecules has
been facilitated by the use of both direct binding assays and
functional competition assays (8-13). Recent studies (14-17)
suggest that peptides that are strong binders to the I-A" class
II molecule share a similar six-residue amino acid sequence
'motif, while those that bind to the I-Ed allele share a different
three- to four-residue motif.
We have described recently a functional competition assay that
appears to be useful for the analysis of peptides recognized by
MHC class l-restricted T cells (18,19). Cytolytic T lymphocyte
(CTL) clones were isolated from DBA/2 mice immunized with
syngeneic (H-2") P815 cells transfected with genes encoding
the human MHC class I molecules HLA-CW3 or HLA-A24
(20). The HLA-specific CTL clones are H-2Kd-restricted and
recognize untransfected P815 cells incubated with synthetic
peptides that correspond to region 170 -182 of the CW3 or A24
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Table 1. Peptides recognized by H-2Kd-or H-2Ld-restricted CTL
Antigen
HLA-CW3
HLA-A24
Influenza NP
P.berghei CS
P198
Influenza HA (A/NT/60/68)
Influenza HA (A/JAP/57)
P91A
MCMV pp89
Peptide
CW3 170-182
A23170-182
NP 147-158 (R-156)
CS 249-260
P198-.14-24
HA 202-212
HA 211-221
HA 523 - 545
P91A-.12-24
pp89 168-176
Sequence8
RYLKNGKETLQRA
RYLENGKETLQRA
TYQRTRALVTG
NDDSYIPSAEKI
KYQAVTTTLEE
RTLYQNVGTYV
YVSVGTSTLNK
VYQILAIYATVAGSLSLIAMMAG
ISTQNHRALDLVA
YPHFMPTNL
MHC restriction
Kd
Kd
Kd
Kd
K«
K"
Kd
Kd
Ld
Ld
Reference
18
18
23
24
45
46
46
47
27
37
aPeptide sequences are given in the one-letter amino acid code: A, alanine; D, aspartate; E, glutamate; F, phenylalanine; G, glycine; H, histidine;
I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; Y, tyrosine.
molecules (18,20). The two HLA peptides could clearly compete
with each other for recognition by the appropriate CTL clones.
Moreover, reciprocal competition also occurred between the HLA
peptides and an unrelated peptide [NP 147-158 (FT,56)] that
is recognized by H-2Kd-restricted CTL specific for the influenza
nucleoprotein (NP) (19).
An analysis of variant HLA-A24 peptides as competitors
identified Tyr171, Thr178 and Leu179 as critical peptide residues
for the interaction of the A24 peptide with the H-2Kd molecule
(21,22). The demonstration that peptide analogs containing the
Ty r . . . Thr-Leu motif with polyproline or polyglycine spacers
functioned as efficient competitors for the HLA and NP peptides
confirmed the importance of the motif (22). Of the three residues,
Tyr171 appeared to be the most crucial for the competitor activity
of the HLA-A24 and CW3 peptides (21,22). It was therefore
intriguing to find that the Tyr residue of the NP peptide was
likewise critical for its competitor activity (22).
As shown in Table 1, all of the peptides thus far defined as
antigens for H-2Kd-restricted CTL contain at least one Tyr
residue. In the present study we present a comparison of the
competitor activity and specificity of four of these unrelated
Kd-restricted peptides. In addition, we compare two peptides
recognized by H-2Ld-restricted CTL, and analyze the structural
basis for the activity of one of them as a potent competitor for
both Kd- and Ld-restricted peptides. Our results indicate that the
amino acid Tyr may function as a strong 'anchor' residue for
many peptides that bind to the H-2Kd molecule.
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Fig. 1. Peptides recognized by H-2Kd-restricted CTL cross-compete
with each other. P815 target cells were incubated with the indicated
concentrations (final) of competitor peptides corresponding to CW3
170-182 ( • ) , CS P.b. 249-250 (O), P198". 14-24 (A), NP
147-158 (R-156) (A), AYP5TLA (•) , and AAP5TLA (D). The antigenic
peptides were CW3 170-182 (0.1 ^M) for CTL-CW3/701.1, CS P.b.
249-260 (0.01 pM) for CTL-CS.B28, P198-.14-24 (0.005 pM) for
CTL-P198.6, and NP 147-158 (R-,S6) (0.002 pM) for CTL-NP T5/5.
Control lysis in the absence of competitor peptides was between 30 and
43% for the four CTL clones, and lysis in the absence of peptides was
Methods
Cells
The isolation and characterization of the CTL clones specific for
HLA-CW3 or HLA-A24 (18,20), of CTL clone NP T5/5 specific
for influenza NP (23), of CTL clone CS.B28 specific for the
Plasmodium berghei circumsporozoite (CS) protein (24), and of
CTL clones P198.6 and P91.6 (25) specific for different antigenic
mutants of the mouse mastocytoma P815 is described elsewhere.
The CTL clones are H-2Kd restricted, except for CTL-P91.6
which is H-2Ld restricted (26,27).
Peptide synthesis and purification
The F-moc, t-Bu strategy for solid phase peptide synthesis
was used as described by Merrifield (28) and by Atherton et al.
(29). HPLC-purified peptides were >90% pure by analytical
HPLC. Lyophilized peptides were dissolved in 0.7% sodium
bicarbonate buffer or water and further diluted in DME containing
5% FCS. Amino acid analysis confirmed the expected peptide
composition.
Cytolytic assay
P815 cells (106) were labeled with 150/tCi sodium [51Cr]-
chromate, as described (30), for 1 h at 37°C and washed three
times. Labeled targets (2 x 103) in 50 pi volumes were added
to wells of V-bottom microtiter plates containing 100 pi volumes
of the appropriate peptide diluted in DME supplemented with
5% FCS and HEPES. CTL (6 x 103 cells) were added in 50 pi
volumes. After a 4 h incubation at 37°C, the supernatants (100 pi)
were harvested for counting. The percentage lysis was calculated
as: 100 x [experimental - spontaneous release)/(total -
spontaneous release)]. For competition experiments, the target
cells were incubated for 15 min with the competitor peptide
(100 ;<l volume) before addition of a suboptimal concentration
of the antigenic peptide (50 pi volume). CTL (50 pi volume) were
added for a further 15 min incubation at room temperature. The
plates were then incubated for 4 h at 37°C. The percent control
lysis was calculated as: 100 x [(% lysis with competitor -
background lysis)/(% lysis without competitor - background
lysis)]. Background lysis represents the percentage lysis of the
target cells in the absence of peptides. The relative competitor
efficiency of the peptides was calculated for the peptide
concentration required to obtain 50% control lysis.
Modeling studies
The H-2Kd model was generated by extension from the
coordinates of the HLA-A2 MHC crystal structure (5), assuming
that the backbone structures, as well as the coordinates of
homologous amino acid side chains, were in essentially identical
positions in the HLA-A2 and H-2Kd molecules. The positions
of the remaining side chains of the H-2Kd molecule were
determined using a statistical protocol that finds the most
probable side-chain orientation of an amino acid residue in a
particular structural context, as determined from observed
distributions in a library of highly refined peptide structures (31).
The resulting structure was minimized for 100 steps of steepest
descent minimization, followed by 1000 steps of conjugate
gradient minimization, using the Discover 2.5 program package
from Biosym Technologies Inc. (La Jolla, CA).
Results
Four different K°'-restricted peptides cross-compete with each
other and share a critical Tyr residue
We have demonstrated previously that the unrelated antigenic
peptides CW3 170-182 and NP 147-158 (FT,56) recognized
in the context of H-2Kd could compete with each other for
recognition by the appropriate CTL clones (19). We now extend
this analysis to two additional Kd-restricted peptides, CS P.b.
249-260 and P198".14-24. As shown in Fig. 1, recognition
of each of the four antigenic peptides could clearly be inhibited
by each of the others, as well as by the pentaproline peptide
analog AYP5TLA. In contrast, minimal or no inhibition was
obtained with the closely related peptide AAP5TLA that contains
Ala (A) in place of the Tyr (Y) residue.
In view of our previous finding that the activity of both the HLA
and NP peptides was decreased by at least 100-fold upon
replacement of Tyr residues with Ala, we performed a similar
analysis on the P198". 14-24 and CS P.b. 249-260 peptides.
Both of the latter two peptides also contain single Tyr residues
(Table 1). Upon replacement of Tyr with Ala the competitor activity
of the CS peptide was reduced by ~ 80-fold, whereas that of
the P198 peptide was reduced by > 1000-fold (Fig. 2).
Ala-substitutions of peptide P198'. 14 -24 identify Tyr15 as the
most critical residue for competitor activity
As described in detail elsewhere (21,22), the three residues
Tyr171, Thr178and Leu179 appear to constitute a binding motif
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Fig. 2. Comparison of the competitor activity of P198 and CS peptides
containing Ala substitutions for Tyr residues. P815 target cells were
incubated with the indicated concentrations (final) of competitor peptides
corresponding to P198 - . 14 - 24 or CS P. b. 249 - 260 containing either
Tyr ( • ) or Ala (O) at positions 15 or 253 in the P198 or CS sequences
respectively. The antigenic peptide CW3 170 -182 was added at a final
concentration of 0.03 ^M. Control lysis by CTL-CW3/1.1 in the absence
of competitor peptides was 68%, and lysis in the absence of peptides
was <3%.
allowing interaction of the A24 peptide with the K« restriction
molecule. Since the same residues occur, albeit with different
spacing, in the P198 sequence, it was of interest to determine
whether they might likewise be involved in binding. Peptides that
correspond to the sequence of P198~.14-24, except for single
Ala substitutions, were tested as competitors for the antigenic
peptide CW3 170-182 (Table 2). By this analysis, the most
critical residue for competitor activity appeared to be Tyr15. The
only other residue that upon substitution with Ala decreased
competitor activity significantly was Leu22, but the effect was
only 4-fold compared with several hundred-fold for Tyr. The
Ala-substituted P198 peptides were also tested as antigen for
CTL clone P198.6 (Table 2). Ala replacement of the P198 peptide
residues Lys14, Tyr15, Gln16, Thr19 and Thr20 reduced
antigenic activity by at least 100-fold.
The Tyr-containing MCMV peptide pp89 168-176 recognized
in the context of H-2Ld competes with Kd-restricted peptides
None of the four synthetic peptides including CW3 170-182,
NP 147-158 (FT,56), P198".14-24 and CS P.b. 249-260,
that are known to be recognized by Kd-restricted CTL could
efficiently inhibit recognition of the Ld-restricted peptide
P91AM2-24 by the CTL clone P91.6 (Fig. 3). In reciprocal
experiments, the P91A peptide was likewise found to be relatively
inefficient as a competitor for the four Kd-restricted peptides (Fig.
3 and data not shown). As a control, we confirmed previously
published results (27) demonstrating that a peptide recognized
by Ld-restricted CTL specific for the pp89 protein of the
mouse MCMV was a very efficient competitor for the P91A
peptide. However, unlike the P91A peptide, the Ld-restricted
MCMV pp89 peptide was also an efficient competitor for the Kd-
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Table 2. Relative activity of Ala-substituted P198 peptides as
antigens and competitors
Peptide Sequence Relative activity8 as:
Competitor Antigen
P198-.14-24 K Y Q A V T T T L E E (1) (1)
K14A A 1.0 <0.001
Y15A - A <0.001 <0.001
Q16A - - A 1.4 <0.001
V18A A 1.5 1.7
T19A A 1.9 <0.001
T20A A 1.0 0.01
T21A A 1.8 1.5
L22A A - - 0.27 0.28
E23A A - 2.6 2.7
E24A A 2.5 4.4
TB6Ab K Y Q A V T T T L E E 1.6 1.4
aCompetitor activity for the Kd-restricted antigenic peptide CW3
170 - 182 was assayed with clone CTL-CW3/1.1. Antigenic activity was
assayed with the P198-specific CTL clone P198.6. The results are
presented as the average values of two separate experiments and are
expressed relative to the activity of peptide P198 - . 14 - 24 as described
in Methods.
bPeptide TB6A represents an independent synthesis of peptide
P198-.14-24.
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Fig. 3. Comparison of peptides recognized by Kd-restricted or
Derestricted CTL as competitors for each other. P815 target cells were
incubated with the indicated concentrations (final) of competitor peptides
CS P.b. 249-260 (A —A), P198".14-24 ( A - - A ) , NP 147-158
(R-,56) (A), CW3 170-182 (•),MCMV pp89 168-176 ( • ) , and
P91A-.12-24 (D). The antigenic peptides were CW3 170-182
(0.03 pM) and P91A~. 12 - 24 (0.005 ^M) for CTL clones CW3/1.1 and
P91.6 respectively. Control lysis by CTL-CW3/1.1 and CTL-P91.6 in the
absence of competitors was 78 and 76% respectively. Lysis in the
absence of peptides was <3°/o.
restricted CW3, P198, NP and CS peptides (Fig. 3 and
data not shown).
The pp89 peptide 168-176 contains a Tyr residue at the
N-terminal end. In view of the importance of Tyr residues in the
four different K^-restricted peptides that we have analyzed (22;
Fig. 2), we considered the possibility that the Tyr residue of the
pp89 peptide might be likewise involved in the interaction of the
peptide with the K<* molecule. For the HLA-A24 and -CW3
peptides we had found that the competitor activity improves
- 5 - to 10-fold upon addition of a single residue (Arg) N-terminal
to the Tyr171 residue (21,22). To test for a similar effect in the
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Fig. 4. The addition of an N-terminal residue to peptide pp89 168 - 176
improves its competitor activity for the CW3 (Kd-restricted) peptide, but
not for the P91A (Ld-restricted) peptide. P815 target cells were incubated
with the indicated concentrations (final) of competitor peptides AYP5TLA
( • ) , AAP5TLA (O), pp89 168-176 (A —A), pp89 167-176
(A - - A), and pp89 167 - 176 (167R) (A). The antigenic peptides were
CW3 170- 182 (0.05 /tM) and P91A".12-24 (0.01 ^M) for CTL clones
CW3/1.1 and P91.6 respectively. Control lysis in the absence of
competitors was 76 and 80% for CTL-CW3/1.1 and CTL-P91.6
respectively. Lysis in the absence of peptides was <4%.
pp89 peptide, we synthesized pp89 peptides with an additional
residue at the N-terminal end. The residue was either Met to
correspond to the natural MCMV sequence, or Arg which is the
residue preceding Tyr in the HLA 170-182 sequence. Both
peptides were at least 20 times more active as competitors for
the CW3 peptide recognized by K^-restricted CTL, but were
several-fold less active as competitors for the P91A peptide
(Fig. 4 and Table 3). The experiment presented in Fig. 4 also
demonstrates that the polyproline-containing peptide analog
AYP5TLA that was shown (Fig. 1) to compete with four different
peptides recognized by K^-restricted CTL, fails to compete with
the P91A peptide.
In a further analysis, a series of Ala-substituted pp89 peptides
corresponding to region 168-176 was synthesized, and the
peptides were compared as competitors for antigenic peptides
recognized by either Ld-restricted or Kd-restricted CTL clones
(Table 3). When tested as competitors for the CW3 peptide
recognized by a Kd-restricted CTL clone, the activity of peptides
with Ala substitutions at Tyr168 or Leu176 was reduced by at
least 10-fold (Table 3). Substitutions at Pro173 and Thr174 also
reduced the competitor activity, but by < 5-fold. Similar results
were obtained with K^-restricted CTL that recognized the P198
antigenic peptide (Table 3).
A different pattern of relative competitor activity was observed
when the Ala-substituted pp89 peptides were tested as
competitors for the P91A peptide that is recognized by Ld-
restricted CTL (Table 3). In that case the competitor activity of
peptides with Ala replacements for the residues Tyr168, Pro169,
Pro173, Asn175 or Leu176 was reduced by at least 30-fold. In
addition, Ala substitutions for His170 and Thr174 resulted in a
5- to 10-fold reduction in competitor activity (Table 3). Only for
residues Phe171 and Met172 was the activity of the substituted
peptides comparable to that of the control pp89 binding. The
different patterns of relative competitor activity clearly suggest
that the apparent capacity of the pp89 peptide to interact with
both Ld and K« molecules depends on distinct, but possibly also
on partly shared structural features of the peptide.
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Table 3. Comparison of Ala-substituted MCMV pp89 peptides as competitors for Ld-restricted and Kd-restricted peptides
Peptide Sequence Relative efficiency as a competitor for antigenic peptidesa
P91A(L<0 CW3(K«) CW3(Kd)
ExpA ExpA ExpB ExpC
N1 Y P H F M P T N L (1) (1) (1) (1)
N2 A 0.011 0.08b 0.06 0.15
N3 A - 0.033 0.64 0.70 1.6
N4 A - - 0.12 0.22 0.23 0.25
N5 A 0.034 0.28 0.25 0.79
N6 A 0.91 0.64 0.58 0.88
N7 A 1.0 0.5 0.54 0.71
N8 - - A 0.18 1.3 1.8 1.9
N9 - A 0.009 0.58 0.58 0.6
012 A 0.015 0.06b 0.04 0.12
011 1.82 1.4 2.6 2.3
N11 M 0.32 29 108 107
N12 R 0.41 22 61 56
^Competition for antigenic peptides P91A".12-24 (0.005 /iM), CW3 170-182 [0.03 pM (ExpA) and 0.05 ^M (ExpB)], and P198".14-24
(0.005 nM) was assayed with CTL clones P91.6, CW3/1.1, and P198.6 respectively. Fifty percent inhibition of lysis for reference peptide N1 as a
competitor was obtained at 0.2 nM for the P91A peptide, at 7 ^ M (ExpA) and 1.4 fiM (ExpB) for the CW3 peptide, and at 15 nM for the P198 peptide.
The values in the table represent the relative concentration of peptide required to obtain 50% inhibition of lysis, compared with the N1 peptide.
Peptide 011 represents an independent synthesis of MCMV pp89 168-176 (N1).
blnhibition was <5O°/o, so the values were calculated at 25% inhibition of lysis.
Discussion
Our study identifies the amino acid Tyr as a common critical
residue for several unrelated antigenic peptides that are
recognized in the context of H-2K<*. The presumed binding of
peptides to MHC class I molecules was assessed indirectly in
a previously described (18,19) functional competition assay.
Complete dose - response curves were obtained for each
individual competitor peptide in order to compare the inhibitory
capacity of the peptides quantitatively. We would also like to
emphasize the advantage of testing competitor peptides in
heterologous antigenic systems. By using CTL clones that
recognize unrelated antigenic peptides, all variants of a peptide
sequence can be compared to the original peptide as
competitors, and the analysis is not limited to those that are
no longer recognized as antigen. In the present study, we
demonstrate that the four unrelated Kd-restricted peptides
CW3 170-182, NP 147-158 (FT
 156), CS P.b. 249-260 and
P198".14-24 all compete reciprocally with each other (Fig.
1) and yet none competes with the ^-restricted peptide
P91AM2-24 (Fig. 3). Moreover, for all four peptides the
competitor activity is reduced by at least 100-fold on substitution
of Tyr residues with Ala (22; Fig. 2).
All three of the additional peptides defined (to date) in the
literature as antigens for Kd-restricted T cells also contain at least
one Tyr residue (Table 1). The occurrence of Tyr in peptide
sequences, however, is not unusual. For example, 44% (25 out
of 57) of the peptides listed in one study as reported T cell
epitopes (32) contain at least one Tyr residue. In this context,
it is interesting to recall that the Tyr-containing peptides NP
50-63 and Y(NANP)3NA that are recognized by H-2Kk- and
IAb-restricted T cells respectively (33,34), could also compete,
although only inefficiently, with Kd-restricted peptides (18,19).
Moreover, the peptides HA 307 -318 and pp89 168 -176 that
are recognized by DR1-and Ld-restricted T cells respectively
(35-37), clearly compete with the Kd-restricted peptide CW3
170-182 (Fig. 3; unpublished results). For both of the latter
peptides the competitor activity was found to be sensitive to Ala
substitution of the Tyr residues (Table 3; unpublished results).
It appears, however, that the presence of a Tyr residue within
a peptide sequence is not sufficient for Kd binding activity since,
for example, the Tyr-containing peptide horse cyt C 39 - 53 failed
to compete (18). The analysis of a larger panel of peptides will
clearly be required to assess the general importance of Tyr
residues for Kd binding activity, and to identify additional
features such as peptide length, the relative position of Tyr, and
the nature of other amino acid side chains in the peptide
sequence that might also influence peptide binding.
For the HLA peptide A24 170 -182, the residues Thr178 and
Leu179 together with Tyr171 appear to be important for optimal
peptide binding. Initially, the putative binding motif Tyr171
. . . Thr178-Leu179 was identified by amino acid substitution of
the A24 peptide. Subsequently, we showed that peptide analogs
containing the motif and polyproline or polyglycine spacer
residues to separate Tyr from the Thr-Leu pair could also function
as competitors (22). For example, a pentaproline analog with the
sequence AYP5TLA was found to be a potent competitor for the
Kd-restricted HLA and NP peptides (22). We now show that the
same analog also competes efficiently with two other Kd-
restricted peptides (CS P.b. 249-260 and P198M4-24) (Fig.
1), but fails to compete with the Ld-restricted peptide
P91AM2-14 (Fig. 4).
Another Kd-restricted peptide, P198".14-24, also contains
a Thr-Leu pair of residues, but the spacing with respect to the
critical Tyr residue differs from that of the HLA peptides by one
residue (Table 1). With the exception of Tyr15, no individual
residue in the P198 peptide could be clearly identified as critical
for peptide binding in an analysis of Ala-substituted peptides
(Table 3). At most, replacement of Leu22 with Ala reduced
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competitor activity by ~4-fold. In contrast, Ala substitutions at
five of the 11 positions reduced by at least 100-fold the activity
of the peptides as antigen for CTL clone .P198.6. Similar
observations in analyses of peptides recognized in the context
of MHC class II molecules have been interpreted as indications
of the stringency of the specificity of the T cell antigen receptor
for peptide-MHC antigenic complexes compared with that of
the MHC molecule for peptides (13).
One interpretation of our results would be that the aromatic
side chain of the amino acid Tyr acts as an 'anchor' to secure
the peptide within the MHC binding site, and that one or more
additional residues provide further stabilization. In this context,
it is noteworthy that the putative peptide binding site of the MHC
class I molecule contains numerous aromatic residues, some of
which are polymorphic (5,6). Moreover, the involvement of a
disproportionate number of aromatic residues has been observed
in the contact region of antigen-antibody complexes (38,39).
According to the model for peptide - MHC interaction proposed
by Garrett et al. (40) our results suggest that the peptide-binding
cleft of the Kd molecule contains at least one 'pocket' that
accommodates Tyr residues of antigenic peptides. In order to
assess this possibility, a model of the H-2Kd MHC molecule was
constructed by extension from the coordinates of the HLA-A2
crystal structure (5). Figure 5(a) shows the accessible contact
surface of the H-2Kd model in the region of the presumed anti-
genic peptide binding site, comprising two sections of a-helix
(residues G56 to N86 of the a-1 domain, and residues N139 to
E173 of the a-2 domain) superimposed on the anti-parallel 13-
sheet formed by the N-terminal stretches of the a-1 and a-2
domains. As illustrated, there are two pronounced cavities in the
molecular surface that offer potential tight binding sites for amino
acid side chains of antigenic peptides. Both 'pockets' could con-
ceivably accommodate the aromatic side chain of Tyr residues.
Figure 5(b and c) illustrates how the conformationally constrained
peptide AYP5TLA that is an effective competitor for K^-restricted
peptides (Fig. 1 and ref. 22) might interact with the H-2Kd
molecule. The model was obtained by docking the peptide to
the H-2Kd model, followed by energy minimization. In the model
shown (Fig. 5b and c), the peptide Tyr side chain fits into a deep
and elongated pocket and makes contact with MHC Tyr residues
155, 156 and 159, while the peptide Tyr OH group accepts an
H-bond from the MHC Gln114 side chain NH2 group. In
agreement with this latter proposed interaction, we have found
recently that a variant analog, AFP5TLA, that contains a Phe
replacement of Tyr was at least 50-fold less active as a competitor
than the original AYP5TLA analog (J. L Maryanski and G.
Corradin, unpublished results). Interactions with the peptide Leu
side chain includes MHC residues W73, S77, T80, Y123, Y84,
T143 and W147. It should, however, be emphasized that many
alternative binding interactions could also occur. For instance,
the peptide might bind in the reverse orientation such that the
peptide Tyr side chain could fit into the smaller pocket that is
defined in part by K« residues V76 and K146 (see Fig. 5a).
Other possible interactions might involve changes in the peptide
Tyr orientation or even shifts of residues within the binding groove,
such as the side chain of MHC Arg97. Nevertheless, the model
shown does allow a simultaneous fit of the peptide Tyr and Leu
residues into pockets on the MHC surface.
As mentioned above, the MCMV peptides pp89 168-176 and
Fig. 5. A model for the interaction of peptide AYP5TLA with the Kd
molecule, (a) The molecular surface of a model of the H-2Kd class I
molecule in the region of the putative antigen binding site. Note the
presence of two pockets on the molecular surface, (b) A van der Waals
model of the conformationally restricted peptide AYP5TLA docked onto
the H-2Kd surface. The model is one of the many potential alternatives
(see Discussion), (c) A side-view section of the bound peptide model
illustrating how the peptide Tyr and Leu side chains might fit into the MHC
surface pockets.
Tyr residues in W-restricted antigenic peptides 1041
167-176 appear to bind to both Ld and Kd MHC molecules
as assessed by our functional competition assay. In BALB/c
(H-2d) mice this region has been defined as an epitope for
Ld-restricted, but not Kd- or Derestricted T cells (36). In view of
our present results, it might be possible to reveal a Kd-restricted
T cell response by stimulating immune lymphocytes with the
longer peptide that was found to be optimal as a competitor for
Kd-restricted peptides. Alternatively, the use of BALB/c-H-2dm2
mice that lack expression of Ld (41) might preferentially select
for Kd-restricted T cells. A number of antigenic peptides have
been shown to bind to more than one MHC class II molecule,
but in some combinations no T cell response can be detected
(11,42). The lack of responsiveness in combinations where in vitro
binding could be demonstrated has been interpreted as evidence
for the existence of 'holes in the T cell repertoire' (42).
In agreement with analyses of peptides that bind to more than
one MHC class II molecule (15,43,44), our results suggest that
both distinct and partially overlapping structural features allow
the interaction of MCMV pp89 peptides with both Ld and Kd
class I MHC molecules. The addition of either Met or Arg
N-terminal to the Tyr168 residue improved Kd competitor activity
by at least 20-fold, whereas that for Ld decreased several-fold.
Ala substitutions at two positions (Tyr168 and Leu176) reduced
Kd competitor activity by - 10-fold and those at other positions
showed at most only marginal effects. In contrast, Ld competitor
activity was sensitive to Ala substitution of both Pro residues
as well as at least four other residues, and for five of these
replacements the activity was reduced by > 30-fold. One possible
explanation for these findings might be that a particular peptide
conformation determined in part bythe Pro residues is necessary
for optimal Ld binding, whereas a less rigid conformation is
required for Kd binding. We are currently attempting to design
structural analogs (22) of the pp89 sequence that might allow
a further discrimination between the Kd and Ld binding activities.
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